These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27272087)

  • 1. Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma.
    Nasca MR; Lacarrubba F; Ferraù F; Micali G
    J Drugs Dermatol; 2016 Jun; 15(6):766-8. PubMed ID: 27272087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 3. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
    Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
    G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.
    Yin VT; Wiraszka TA; Tetzlaff M; Curry JL; Esmaeli B
    Ophthalmic Plast Reconstr Surg; 2015; 31(4):e112-5. PubMed ID: 24833447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
    Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
    J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.
    Boussemart L; Routier E; Mateus C; Opletalova K; Sebille G; Kamsu-Kom N; Thomas M; Vagner S; Favre M; Tomasic G; Wechsler J; Lacroix L; Robert C
    Ann Oncol; 2013 Jun; 24(6):1691-7. PubMed ID: 23406731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Kiyota N; Ejima Y; Nakajima K; Nishigori C
    Eur J Dermatol; 2017 Apr; 27(2):177-178. PubMed ID: 27873735
    [No Abstract]   [Full Text] [Related]  

  • 13. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
    Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
    Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
    Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
    Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib and radiosensitization.
    Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
    JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib-induced pityriasis amiantacea: a case report.
    Bilgiç Ö
    Cutan Ocul Toxicol; 2016 Dec; 35(4):329-31. PubMed ID: 26513697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case of vemurafenib-induced Sweet's syndrome.
    Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
    J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-induced neutrophilic panniculitis.
    Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
    Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Painful nipple hyperkeratosis secondary to vemurafenib.
    Carr ES; Brown SC; Fiala KH
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.